Prestige Biopharma to Participate in BIO USA 2026, Targeting Global Market Expansion

Prestige Biopharma to Advance Antibody Therapeutics and
Biosimilar Partnerships at BIO USA 2026

Prestige Biopharma to Participate in BIO USA 2026, Targeting Global Market Expansion

Prestige Biopharma will participate in the BIO International Convention 2026 (BIO USA 2026), taking place in San Diego, California, from June 22 to 25. At the event, the company plans to pursue a dual-track strategy focused on advancing global partnerships for its antibody therapeutics pipeline and expanding commercialization opportunities for its biosimilar portfolio.

On the antibody therapeutics front, Prestige Biopharma will actively pursue co-development and licensing discussions for PBP1510 and PBP1710.

PBP1510 is a first-in-class monoclonal antibody that selectively targets PAUF (Pancreatic Adenocarcinoma Upregulated Factor), a protein overexpressed in pancreatic cancer. The candidate is currently progressing toward initiation of a Phase 2a clinical trial later this year.

PBP1710 is an investigational antibody targeting CTHRC1 (Collagen Triple Helix Repeat Containing 1), a protein overexpressed in various solid tumors. The candidate is being developed under Korea’s National Drug Development Program.

In the biosimilar segment, the company will focus on expanding commercialization opportunities for VASFORDA® (HD204), a biosimilar referencing Avastin®, and securing North American commercialization partners for TUZNUE® (HD201), a biosimilar referencing Herceptin®.

VASFORDA® is currently undergoing regulatory and commercialization preparations for entry into the North American market. Manufacturing partner Prestige Biologics continues to strengthen its production and quality systems to support regulatory inspections and approval processes worldwide. Alongside North American regulatory activities, the company is also seeking additional distribution and commercialization partners in global markets.

Leveraging the integrated value chain of the Prestige Biopharma Group—from development and manufacturing to commercialization—the company plans to engage with global pharmaceutical and biotechnology companies to discuss co-development and business opportunities across its broader pipeline.

In addition, Prestige Biopharma will showcase its capabilities in subcutaneous (SC) formulation technologies for antibody therapeutics and its AI-driven research, development, and biomanufacturing platform. The company will present its AI applications in target discovery, antibody optimization, bioprocess development, and quality prediction, while also sharing updates on next-generation antibody delivery technologies and exploring potential strategic collaborations

Source : Asia Economy (https://www.asiae.co.kr/article/2026061608300970766)